In 2025, Europe’s healthtech ecosystem showed strong funding momentum, with capital concentrated in large rounds across biotech, medtech, digital health, and AI-enabled healthcare. The biggest deals came from companies such as Oura Health, Isomorphic Labs, Verdiva Bio, Tubulis, and Neko Health, highlighting investor interest in both consumer health platforms and advanced life sciences.
By country, the UK stood out as the most active market, with major rounds across AI drug discovery, biotech, surgical robotics, digital care, and diagnostics. Switzerland also showed strong depth, particularly in biotech and medtech, while Germany, the Netherlands, France, Spain, and the Nordics remained important contributors.
By round type, the market was led by a mix of large growth rounds and strong Series A and Series B activity. Series A deals showed continued appetite for early clinical and platform development, while Series B and later rounds reflected investor support for companies moving toward commercialisation, clinical expansion, or international growth.
Overall, 2025 pointed to a maturing European healthtech market, where capital flowed to companies with clear clinical, technological, or commercial validation, while early-stage innovation remained active across a broad range of European hubs (for more detailed analyses of the European technology ecosystem, check out Tech.eu’s annual report: European Tech 2025 - The Big Picture).
Here are ten healthtech companies that raised the most in 2025.
Oura Health (Finland)
Amount raised in 2025: $900M
Oura Health is a Finnish company that develops the Oura Ring, a smart wearable that continuously tracks sleep, activity, heart rate, and other biometric data. Through its mobile app, it delivers personalised insights to support users’ health and wellbeing.
In 2025, the company raised more than $900 million in a funding round that valued it at around $11 billion. The capital is intended to enhance AI capabilities, drive product development, expand global reach, and introduce new health features.
Isomorphic Labs (UK)
Amount raised in 2025: $600M
Isomorphic Labs is a London-based artificial intelligence company focused on transforming drug discovery through advanced machine learning.
A spin-out of DeepMind, it builds AI models based on technologies such as AlphaFold to predict biological structures and design new medicines more quickly and efficiently, with the aim of accelerating breakthroughs in human health.
In 2025, Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from Alphabet and Google Ventures, highlighting continued backing from its parent ecosystem.
Verdiva Bio (UK)
Amount raised in 2025: $411M
Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.
Its pipeline includes oral and injectable treatments designed to improve efficacy, convenience, and long-term outcomes, with a focus on patient-friendly options such as once-weekly dosing. The company leverages advances in gut-brain biology to create innovative medicines aimed at addressing significant unmet medical needs in global health.
In 2025, Verdiva Bio launched with $411 million raised in a Series A for advanced obesity therapies.
Tubulis Technologies (Germany)
Amount raised in 2025: €308M
Tubulis is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.
Its proprietary platform technologies enable the creation of highly stable, targeted therapies designed to deliver anti-cancer agents directly to tumours, improving efficacy while reducing side effects. The company is advancing a pipeline of ADC candidates for solid and hematologic tumours, with a focus on expanding the therapeutic potential of precision oncology and addressing areas of high unmet medical need.
Tubulis raised €308 million in a Series C funding round in 2025 to advance the clinical development of its lead cancer therapy TUB-040, including expanding into earlier treatment lines and additional indications.
Neko Health (Sweden)
Amount raised in 2025: $260M
Neko Health is a healthtech company focused on preventive healthcare and early disease detection.
It develops advanced scanning systems that combine sensors, imaging, and AI to collect and analyse large amounts of health data in a non-invasive way. Through its health centres, the company provides comprehensive body scans and immediate, doctor-led consultations, aiming to shift healthcare from reactive treatment to proactive prevention.
In 2025, Neko Health raised $260 million in a Series B for preventative health scanning tech.
Ortivity (Germany)
Amount raised in 2025: €200M
Ortivity is a Munich-based healthtech company building an integrated network of outpatient orthopaedic practices and surgical centres across Germany.
Founded by physicians, it connects clinics, physiotherapy centres, and medical providers into a unified platform delivering diagnostics, treatment, surgery, and aftercare. Its model focuses on improving access, efficiency, and quality of care through a physician-led approach and the use of digital solutions, aiming to modernise orthopaedic services and shift care from inpatient to outpatient settings.
Ortivity secured €200 million in 2025 to expand outpatient orthopaedic care.
CMR Surgical (UK)
Amount raised in 2025: $200M
CMR Surgical is a medical device company developing robotic systems for minimally invasive surgery.
Its flagship product, the Versius surgical robot, is designed to assist surgeons in performing precise procedures while improving access to keyhole surgery. The company focuses on enhancing surgical outcomes, reducing recovery times, and making advanced robotic-assisted surgery more accessible across healthcare systems.
In 2025, CMR Surgical raised over $200 million to expand global deployment of its Versius system, including entry into the US market, and to advance product development and innovation.
Azafaros (Netherlands)
Amount raised in 2025: €132M
Azafaros is a clinical-stage biotechnology company developing disease-modifying therapies for rare genetic and metabolic disorders.
Founded in 2018, the company focuses on small-molecule treatments targeting lysosomal storage diseases. Its lead candidate, nizubaglustat, is an orally available therapy designed to address underlying disease mechanisms, with the aim of delivering new treatment options for patients with limited or no existing therapies.
In 2025, Azafaros completed an oversubscribed €132 million Series B funding round.
Cera (UK)
Amount raised in 2025: $150M
Cera is a London-based healthtech company providing digital-first home healthcare services.
It combines a network of carers and nurses with AI-driven technology to deliver care, monitoring, and support in patients’ homes, aiming to improve outcomes, reduce hospitalisations, and shift healthcare from hospitals to community settings.
In 2025, Cera raised a $150 million funding round to expand its AI platform, increase service diversity, and support operational growth.
DistalMotion (Switzerland)
Amount raised in 2025: $150M
Distalmotion is a medtech company developing robotic systems for minimally invasive surgery.
Founded as a spin-off from EPFL, it created the DEXTER surgical robot, designed to simplify operations and integrate into existing hospital workflows. The company aims to expand access to robotic surgery by reducing complexity and enabling more surgeons and healthcare facilities to adopt advanced, precise surgical techniques across a range of procedures.
Distalmotion raised $150 million in a 2025 Series G round to expand deployment of its DEXTER surgical robot in the US.
Would you like to write the first comment?
Login to post comments